Hikma Pharmaceuticals Plc (HIK) Downgraded to “Hold” at Stifel Nicolaus
Stifel Nicolaus downgraded shares of Hikma Pharmaceuticals Plc (LON:HIK) to a hold rating in a report released on Tuesday. Stifel Nicolaus currently has GBX 1,320 ($17.07) price objective on the stock, down from their prior price objective of GBX 2,300 ($29.75).
Several other equities research analysts have also recently issued reports on HIK. HSBC Holdings plc reaffirmed a reduce rating and issued a GBX 1,800 ($23.28) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, May 5th. Numis Securities Ltd reaffirmed a buy rating and issued a GBX 2,350 ($30.39) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, May 11th. J P Morgan Chase & Co reduced their target price on Hikma Pharmaceuticals Plc from GBX 2,400 ($31.04) to GBX 1,800 ($23.28) and set a neutral rating on the stock in a report on Friday, May 12th. Jefferies Group LLC cut Hikma Pharmaceuticals Plc to an underperform rating and reduced their target price for the stock from GBX 2,162 ($27.96) to GBX 1,450 ($18.75) in a report on Wednesday, May 17th. Finally, Citigroup Inc. reaffirmed a neutral rating and issued a GBX 1,550 ($20.05) target price on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the stock. Hikma Pharmaceuticals Plc has an average rating of Hold and a consensus target price of GBX 1,574.18 ($20.36).
Shares of Hikma Pharmaceuticals Plc (LON HIK) opened at 1261.00 on Tuesday. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00. The company has a 50-day moving average price of GBX 1,345.28 and a 200 day moving average price of GBX 1,733.12. The firm’s market capitalization is GBX 3.03 billion.
WARNING: “Hikma Pharmaceuticals Plc (HIK) Downgraded to “Hold” at Stifel Nicolaus” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/30/hikma-pharmaceuticals-plc-hik-downgraded-to-hold-at-stifel-nicolaus.html.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.